Portal de investigação
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE.
Unidades de investigação
Abstract
Filiações
Filiações não disponíveis
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Dewan P,Ferreira JP,Butt JH,Petrie MC,Abraham WT,Desai AS,Dickstein K,Kober L,Packer M,Rouleau JL,Stewart S,Swedberg K,Zile MR,Solomon SD,Jhund PS,McMurray JJV. Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE. Eur. J. Heart Fail. 2023. 25. (5):p. 687-697. IF:18,200. (1).
